摘要
目的: 本研究旨在分析胱硫醚β合酶(CBS)是否在肝细胞癌(HCC)耐药中起作用。 方法: 采用MTS法检测化疗药物阿霉素(DOX)和舒尼替尼对肝癌细胞存活和生长的影响。通过细胞内阿霉素积累试验,评价阿霉素和舒尼替尼对肝癌细胞的敏感性及多药耐药相关蛋白P-糖蛋白(P-gp)的作用。采用亚甲蓝法对硫化氢产量进行了定量分析。细胞内活性氧的产生用DCFHDA分析定量。采用刮伤法和穿孔法测定细胞迁移和侵袭情况。蛋白质的表达通过蛋白质印迹分析检测。 结果: 高CBS表达的HepG2细胞对DOX和sunitinib的敏感性较低,CBS的敲除显著提高了HepG2细胞对DOX和sunitinib的敏感性。相比之下,CBS过度表达增加了BEL-7404细胞对DOX和舒尼替尼的抵抗力。此外,CBS的过度表达导致了BEL-7404细胞P-gp表达水平的上调和DOX积累的减少。在进一步的机制研究中,我们发现Stat3/Akt/Bcl-2通路的激活、活性氧抑制以及提高肝癌细胞的转移能力是肝细胞癌耐药的主要原因。 结论: CBS过度表达导致肝癌细胞抵抗.
关键词: 胱硫醚β合酶,多药耐药,转移,肝癌,DOX,GST。
Current Molecular Medicine
Title:Cystathionine β-synthase Induces Multidrug Resistance and Metastasis in Hepatocellular Carcinoma
Volume: 18 Issue: 7
关键词: 胱硫醚β合酶,多药耐药,转移,肝癌,DOX,GST。
摘要: Objective: This study aims to analyze whether Cystathionine β-synthase (CBS) plays roles in hepatocellular carcinoma (HCC) drug resistance.
Methods: MTS assay was used to detect the effect of chemotherapeutic drugs doxorubicin (DOX) and sunitinib on HCC cell viability and cell growth. Intracellular doxorubicin accumulation assay was performed to evaluate the sensitivity of DOX and sunitinib in HCC cells and the function of multidrug resistance-associated protein Pglycoprotein (P-gp). Quantification of H2S production was performed using the methylene blue method. Production of intracellular ROS was quantified using the DCFHDA assay. The scratch wound and transwell assays were used to determine the cell migration and invasion. Expression of proteins was tested by western blot analysis.
Results: HepG2 cells with high CBS expression were less sensitive to DOX and sunitinib and knockdown of CBS significantly elevated the sensitivity to DOX and sunitinib in HepG2 cells. In contrast, CBS overexpression increased the resistance of DOX and sunitinib in BEL-7404 cells. Moreover, the overexpression of CBS caused the up-regulation of the expression level of P-gp and the decrease of DOX accumulation in BEL-7404 cells. In further mechanism research, we found that STAT3/Akt/Bcl-2 pathway activation, reactive oxygen species (ROS) inhibition as well as enhancement of the metastatic ability of hepatoma cells were responsible for the HCC drug resistance.
Conclusion: CBS overexpression conferred HCC cell resistance.
Export Options
About this article
Cite this article as:
Cystathionine β-synthase Induces Multidrug Resistance and Metastasis in Hepatocellular Carcinoma, Current Molecular Medicine 2018; 18 (7) . https://dx.doi.org/10.2174/1566524019666181211162754
DOI https://dx.doi.org/10.2174/1566524019666181211162754 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance
Current Medicinal Chemistry Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Anti-hyperglycemic Properties of a Purified Proteinaceous Protease Inhibitor from Macrotyloma Uniflorum Seeds
Current Topics in Medicinal Chemistry Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry The RNA-Unwinding Activity of Hepatitis C Virus Non-Structural Protein 3 (NS3) Is Positively Modulated by Its Protease Domain
Protein & Peptide Letters Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Part I: Targeted Particles for Cancer Immunotherapy
Current Drug Delivery The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver
Current Pharmaceutical Design Proteolytic Cleavage of Notch: “HIT and RUN”
Current Molecular Medicine Chebulagic Acid Synergizes the Cytotoxicity of Doxorubicin in Human Hepatocellular Carcinoma Through COX-2 Dependant Modulation of MDR-1
Medicinal Chemistry Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Epigenetic Modulation Using Small Molecules - Targeting Histone Acetyltransferases in Disease
Current Medicinal Chemistry Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry PPARα/HNF4α Interplay on Diversified Responsive Elements. Relevance in the Regulation of Liver Peroxisomal Fatty Acid Catabolism
Current Drug Metabolism